Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kamada Ltd. stock logo
KMDA
Kamada
$7.90
+0.5%
$6.89
$4.83
$9.16
$451.99M0.9495,894 shs35,311 shs
Organogenesis stock logo
ORGO
Organogenesis
$3.61
+2.0%
$3.62
$2.28
$6.71
$449.06M1.631.14 million shs910,163 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$1.45
+2.8%
$1.94
$0.82
$3.10
$115.43M-0.2560,434 shs708,182 shs
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.08
+0.5%
$17.77
$13.30
$26.79
$408.32M1.154,824 shs37,540 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kamada Ltd. stock logo
KMDA
Kamada
+0.51%+9.42%+13.67%+17.04%+58.00%
Organogenesis stock logo
ORGO
Organogenesis
+1.98%+10.40%+21.55%-19.78%+39.92%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
+2.84%+3.57%-7.05%-43.80%+17.89%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
+0.47%-3.42%-1.92%-11.69%-28.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Kamada Ltd. stock logo
KMDA
Kamada
3.6084 of 5 stars
3.43.00.00.02.61.72.5
Organogenesis stock logo
ORGO
Organogenesis
4.5041 of 5 stars
3.33.00.04.32.74.20.6
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
2.6734 of 5 stars
3.54.00.00.00.60.01.9
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
2.5636 of 5 stars
3.83.00.00.02.70.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kamada Ltd. stock logo
KMDA
Kamada
2.75
Moderate Buy$14.6785.65% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.50
Moderate Buy$5.5052.35% Upside
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$15.00934.48% Upside
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
3.50
Strong Buy$45.00163.47% Upside

Current Analyst Ratings Breakdown

Latest PLX, ORGO, PRTC, and KMDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Kamada Ltd. stock logo
KMDA
Kamada
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/8/2025
Kamada Ltd. stock logo
KMDA
Kamada
Sidoti
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kamada Ltd. stock logo
KMDA
Kamada
$160.95M2.82$0.49 per share15.99$4.51 per share1.75
Organogenesis stock logo
ORGO
Organogenesis
$482.04M0.95$0.21 per share16.97$2.09 per share1.73
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$59.76M1.93$0.08 per share17.80$0.47 per share3.09
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$4.83M84.94$2.40 per share7.13$17.04 per share1.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kamada Ltd. stock logo
KMDA
Kamada
$14.46M$0.2927.2424.690.959.60%6.31%4.43%8/13/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.04N/A4.68N/A-21.03%-30.89%-11.74%N/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$27.78MN/A0.00N/AN/AN/AN/AN/A7/30/2025 (Estimated)

Latest PLX, ORGO, PRTC, and KMDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Kamada Ltd. stock logo
KMDA
Kamada
$0.07$0.07N/A$0.07$154.06 million$44.02 million
5/9/2025Q1
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A-$0.05N/AN/AN/AN/A
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Kamada Ltd. stock logo
KMDA
Kamada
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kamada Ltd. stock logo
KMDA
Kamada
N/A
3.30
1.93
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/A
9.33
9.33

Institutional Ownership

CompanyInstitutional Ownership
Kamada Ltd. stock logo
KMDA
Kamada
20.38%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.04%

Insider Ownership

CompanyInsider Ownership
Kamada Ltd. stock logo
KMDA
Kamada
36.10%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.50%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Kamada Ltd. stock logo
KMDA
Kamada
36057.51 million36.75 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20079.61 million69.00 millionOptionable
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
10024.02 million22.75 millionNot Optionable

Recent News About These Companies

Why This Biotech Stock Just Doubled In A Single Day
Leerink Partners Keeps Their Buy Rating on PureTech Health (PRTC)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Kamada stock logo

Kamada NASDAQ:KMDA

$7.90 +0.04 (+0.51%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$7.89 -0.01 (-0.13%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$3.61 +0.07 (+1.98%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$3.55 -0.06 (-1.63%)
As of 07:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$1.45 +0.04 (+2.84%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$1.44 -0.01 (-0.62%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$17.08 +0.08 (+0.47%)
Closing price 06/26/2025 03:58 PM Eastern
Extended Trading
$17.84 +0.76 (+4.43%)
As of 07:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.